Breaking Finance News

A statement released earlier today by RBC Capital Markets about Gilead Sciences (NDAQ:GILD) bumps the target price to $94.00

RBC Capital Markets bumped up the target of Gilead Sciences (NDAQ:GILD) to $94.00 stating a potential upside of 0.14%.

On 9/05/2017, Wells Fargo released a statement for Gilead Sciences (NDAQ:GILD) bumped up the target price from $73.00 to $81.00 that suggested a downside of -0.02%.

Boasting a price of $82.63, Gilead Sciences (NDAQ:GILD) traded 1.08% higher on the day. With the last stock price close up 18.63% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Gilead Sciences has recorded a 50-day average of $76.95 and a two hundred day average of $70.12. Volume of trade was down over the average, with 4,609,352 shares of GILD changing hands under the typical 10,144,300

Performance Chart

Gilead Sciences (NDAQ:GILD)

With a total market value of $0, Gilead Sciences has 52 week low of $63.76 and a 52 week high of $86.27 with a P/E ratio of 9.03 .

In addition to RBC Capital Markets reporting its target price, a total of 19 firms have issued a report on the stock. The consensus target price is $111.05 with 7 firms rating the stock a strong buy, 9 firms rating the stock a buy, 9 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Gilead Sciences (NDAQ:GILD)

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.